



March 21, 2005

6201 SOUTH FREEWAY
FORT WORTH, TEXAS 76134-2099
(817) 293-0450(817) 551-4321 TELEPHONE
(817) 551-4610 TELECOPIER

INTELLECTUAL PROPERTY LAW AND R&D COUNSEL

- TELEFAX TRANSMISSION COVER SHEET -	
TO: Office of Initial Patent Examination's Filing Receipt Corrections, U.S. Patent and Trademark Office	
FAX: 703 - 746 - 9195	
FROM: Teresa J. Schultz	RE: USPN 10/511,414
MESSAGE: See attached Request For Correction Of Filing Receipt [1 pg]; and copy of marked-up Filing Receipt [2 pp].	
THIS FAX CONSISTS OF <u>4</u> PAGES INCLUDING THIS COVER SHEET.	
NOTE: If you do not receive all pages, please call Barbara McKenzie at (817) 551-4447 as soon as possible. THANK YOU! Confirmation copy will NOT be sent.	
<small>Confidentiality Notice: This facsimile transmission and the documents accompanying it may contain work product and/or privileged and confidential information intended only for the use of the individual or entity named above. If you have received this facsimile in error, please immediately notify us by telephone. Thank you.</small>	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: David P. BINGAMAN

Serial No. 10/511,414 (Conf. #9926)

Filed: 14 October 2004

Examiner:

For: METHOD OF TREATING VASCULAR
ENDOTHELIAL GROWTH FACTOR
MEDIATED VASCULAR DISORDERS

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being
facsimile transmitted to the Patent and Trademark
Office (Fax No. 703-746-9195) on 21 March 2005.Name: Barbara McKenzieSignature: Barbara McKenzieREQUEST FOR CORRECTION OF FILING RECEIPTCommissioner for Patents
Attn: Office of Initial Patent Examination's Customer Service Center
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants hereby request correction of the official filing receipt issued in connection with the above-identified patent application. A copy of the filing receipt as originally issued is attached, with the correction noted in red.

As reflected on the attached filing receipt copy please delete ~~Berleson~~ from the Applicant John M. Yanni's address and replace with Burleson.

In order to avoid future confusion, Applicants respectfully request that a corrected filing receipt be issued to reflect the correct information.

Respectfully submitted,

ALCON RESEARCH, LTD.

Date: 21 March 2005By: Teresa J. SchultzTeresa J. Schultz
Registration No. 40,526

Address for Correspondence:

Teresa J. Schultz
R&D Counsel, Q-148
Alcon Research, Ltd.
6201 South Freeway
Fort Worth, Texas 76134-2099
Phone: (817) 551-4321Attorney Docket No.: 2380 US F



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/511,414	10/14/2004	1617	950	2380 US F	2	10	2

CONFIRMATION NO. 9926

Alcon Research
6201 South Freeway
Fort Worth, TX 76134-2099

FILING RECEIPT



OC000000015344129

Date Mailed: 03/10/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

David P Bingaman, Fort Worth, TX;
Michael K. Kapin, Arlington, TX;
Daniel A. Gamache, Arlington, TX;
Gustav Graff, Cleburne, TX;
John M. Yanni, ~~Burleson~~, TX;

Burleson

Power of Attorney:

James Arno-26145
Gregg Brown-30613
Barry Copeland-34801
Jeffrey Schira-34922
Patrick Ryan-36263

W Lee-39743
Teresa Schultz-40526
Armando Pastrana Jr-44997

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US03/11769 04/16/2003
which claims benefit of 60/377,429 05/03/2002

Foreign Applications

Projected Publication Date: To Be Determined - pending completion of Security Review

Non-Publication Request: No

RECEIVED

MAR 18 2005

R & D COUNSEL

Early Publication Request: No

Title

Method of treating vascular endothelial growth factor mediated vascular disorders

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).